Q32 Bio Net Worth
Q32 Bio Net Worth Breakdown | QTTB |
Q32 Bio Net Worth Analysis
Q32 Bio's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Q32 Bio's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Q32 Bio's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Q32 Bio's net worth analysis. One common approach is to calculate Q32 Bio's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Q32 Bio's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Q32 Bio's net worth. This approach calculates the present value of Q32 Bio's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Q32 Bio's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Q32 Bio's net worth. This involves comparing Q32 Bio's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Q32 Bio's net worth relative to its peers.
Enterprise Value |
|
To determine if Q32 Bio is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Q32 Bio's net worth research are outlined below:
| Q32 Bio generated a negative expected return over the last 90 days | |
| Q32 Bio has high historical volatility and very poor performance | |
| Q32 Bio has high likelihood to experience some financial distress in the next 2 years | |
| Q32 Bio was previously known as Homology Medicines and was traded on NASDAQ Exchange under the symbol FIXX. | |
| The company reported the previous year's revenue of 1.16 M. Net Loss for the year was (112.96 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Q32 Bio generates negative cash flow from operations | |
| About 74.0% of the company shares are owned by institutional investors | |
| Latest headline from gurufocus.com: Carlyle Group Inc.s Strategic Reduction in ZoomInfo Technologies Inc. |
Follow Q32 Bio's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 556.56 M.Market Cap |
|
Project Q32 Bio's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.37) | (0.39) | |
| Return On Capital Employed | (0.31) | (0.33) | |
| Return On Assets | (0.37) | (0.39) | |
| Return On Equity | (1.55) | (1.47) |
When accessing Q32 Bio's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Q32 Bio's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Q32 Bio's profitability and make more informed investment decisions.
Please note, the presentation of Q32 Bio's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Q32 Bio's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Q32 Bio's management manipulating its earnings.
Evaluate Q32 Bio's management efficiency
As of November 22, 2024, Return On Tangible Assets is expected to decline to -0.39. In addition to that, Return On Capital Employed is expected to decline to -0.33. At present, Q32 Bio's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 1.8 M, whereas Total Assets are forecasted to decline to about 190.9 M. Q32 Bio's management efficiency ratios could be used to measure how well Q32 Bio manages its routine affairs as well as how well it operates its assets and liabilities.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 22.72 | 43.26 | |
| Tangible Book Value Per Share | 22.72 | 43.26 | |
| Enterprise Value Over EBITDA | 0.03 | 0.03 | |
| Price Book Value Ratio | 0.48 | 0.46 | |
| Enterprise Value Multiple | 0.03 | 0.03 | |
| Price Fair Value | 0.48 | 0.46 | |
| Enterprise Value | -3.2 M | -3.1 M |
Understanding the operational decisions made by Q32 Bio management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Revenue -12.8 M | Revenue Per Share (1.24) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Q32 Bio insiders, such as employees or executives, is commonly permitted as long as it does not rely on Q32 Bio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Q32 Bio insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Q32 Bio time-series forecasting models is one of many Q32 Bio's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Q32 Bio's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Q32 Bio Earnings per Share Projection vs Actual
Q32 Bio Corporate Management
| Saul Fink | Chief Officer | Profile | |
| Kathryn MBA | Manufacturing Chemistry | Profile | |
| Lee MBA | Chief Officer | Profile | |
| Maria MPH | Executive Operations | Profile | |
| David JD | Senior People | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Q32 Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For information on how to trade Q32 Stock refer to our How to Trade Q32 Stock guide.You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Q32 Bio. If investors know Q32 will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Q32 Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.50) | Revenue Per Share (1.24) |
The market value of Q32 Bio is measured differently than its book value, which is the value of Q32 that is recorded on the company's balance sheet. Investors also form their own opinion of Q32 Bio's value that differs from its market value or its book value, called intrinsic value, which is Q32 Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Q32 Bio's market value can be influenced by many factors that don't directly affect Q32 Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Q32 Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Q32 Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Q32 Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.